



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2023-24/37
July 6, 2023

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, Please find attached herewith press release on “Aarti Drugs Limited won Pharmexcil Outstanding Exports Awards 2021-22”.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: A54527



Won Pharmexcil Outstanding Exports Award 2021-2022

Mumbai, 06th July 2023

Aarti Drugs Limited (Aarti Drugs) (NSE: AARTIDRUGS; BSE:524348), a Mumbai based diversified and fully integrated pharmaceutical company, with interests in Active Pharmaceutical Ingredients (API), Formulation, Specialty Chemicals and Intermediates has won Pharmexcil Outstanding Exports Award 2021-2022.

Company has received **Export Performance Award – API & Intermediaries Gold Star** for the year 2021-22 on July 5th, 2023, in recognition of commendable contribution to the pharmaceutical export of India.

A ministry set up by the Government of India as a gateway to global pharma trade, Pharmexcil presents awards each year to salute those companies that demonstrate excellence in developing proprietary products granted patents throughout the world. The awards were presented during the “**iPHEX 9th edition of Indian Pharmaceutical Exhibition**” organized by the Pharmaceuticals Export Promotion Council (Pharmexcil) and sponsored by Department of Commerce & Industry, Government of India where all the major India Pharmaceutical companies had participated. Here the evaluation for the award is based on the value of exports by a company to all the regions of the world and the coverage in terms of the number of countries to which export is made.

Commenting on the same, **Mr. Adhish Patil, CFO & COO, Aarti Drugs Limited said,**

“This recognition by Pharmexcil once again for our profound dedication to the innovation and science behind the products we develop and market worldwide is gratifying and inspiring. We shall, as always, strive to continue contributing our best in every way possible to achieve bigger goals in future.”





About Aarti Drugs Limited

Aarti Drugs Limited was established in the year 1984 and forms part of \$6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Speciality Chemicals and produces Formulations with its wholly-owned subsidiary-Pinnacle Life Science Private Limited. The Company have total 12 manufacturing facilities out of which 9 manufacturing facilities are in Maharashtra, 2 Manufacturing facilities in Gujarat and 1 Manufacturing facility of Pinnacle is located at Himachal Pradesh. Products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.

For more information, please visit www.aartidrugs.co.in

For more information, please contact

Company:
Aarti Drugs Limited

Investor Relations (IR)
Strategic Growth Advisors Pvt. Ltd.



CIN: L37060MH1984PLC055433

Mr. Rushikesh Deole
investorrelations@aartidrugs.com
+91 22 24048199



CIN: U74140MH2010PTC204285

Mr. Deven Dhruva / Mr. Harsh Shah
deven.dhruva@sgapl.net / harsh.shah@sgapl.net
+91 98333 73300 / +91 97689 74808

Safe Harbor

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.